Evidence map›Paper›PMID 41794353›Full record

ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2026

The Roles of A Proliferation-Inducing Ligand (APRIL) and B-Cell Activating Factor (BAFF) in IgA Nephropathy.

Colin Reily, Jan Novak, Dana V Rizk

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Nephrin autoimmunity: signal, noise, and a path to clarity.The Journal of clinical investigation · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Colin ReilyDivision of Nephrology, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Jan NovakDepartment of Microbiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Dana V RizkDivision of Nephrology, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: drizk@uabmc.edu.

Funding

Elucidating IgA Nephropathy through Genetic Studies of IgA1 GlycosylationR01DK082753 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GHARAVI, ALI G, NOVAK, JAN · 2009 to 2024
$8.7M
Molecular Basis of Pathogenicity of IgA1-containing Immune ComplexesR01DK078244 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JAN NOVAK · 2007 to 2026
$6.0M
Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune DiseaseR01AI149431 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GREEN, TODD JASON, NOVAK, JAN · 2020 to 2024
$2.6M
Distinct Glycophenotypes with Abnormal Signaling Define a Subpopulation of B cells Responsible for Production of Galactose-Deficient IgA1, the Main Autoantigen in IgA NephropathyR01DK134489 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Colin Robert Reily · 2023 to 2026
$1.9M
Molecular Basis of Pathogenicity of IgA1-containing Immune ComplexesR56DK078244 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NOVAK, JAN · 2012 to 2012
$92k
NIAID NIH HHS R01 AI149431NIDDK NIH HHS R01 DK078244NIDDK NIH HHS R01 DK082753NIDDK NIH HHS R01 DK134489NIDDK NIH HHS R56 DK078244
6 · The paper itself

Abstract

In IgA nephropathy (IgAN), elevated levels of the circulating autoantigen galactose-deficient IgA1 are critical to disease pathogenesis. Abnormal B-cell glycosylation pathways produce the autoantigen that, on recognition by autoantibodies, forms immune complexes. Genetic as well as in vitro, in vivo, and human immunologic studies have identified APRIL (a proliferation-inducing ligand) and BAFF (B-cell activating factor) as key cytokines controlling B-cell development and the differentiation of antibody-secreting cells. Targeting APRIL with or without BAFF is emerging as a viable strategy for the treatment of IgAN and nascent data from global clinical trials are showing very promising results.

Indexed as

B-Cell Activating FactorGlomerulonephritis, IGATumor Necrosis Factor Ligand Superfamily Member 13AnimalsB-LymphocytesHumansB-Cell Activating FactorTNFSF13B protein, humanTNFSF13 protein, humanTumor Necrosis Factor Ligand Superfamily Member 13APRILBAFFB cellIgANIgAN treatment

Identifiers

PMID41794353
PMCPMC13078102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.